Result: A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2022

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

Cancers. - 14, 12 (2022) , 3031, ISSN: 2072-6694

*DOI*:

10.3390/cancers14123031

*Result*: A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT